Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Authors: Herst et al. Link to paper:

Journal/ Pre-Print: BioRxiv

Key Words: Ebola, CTL vaccine, COVID-19, controller

Research Highlights 

1. A single vaccine comprising adjuvant (CpG) and peptide (NP44-52 (YQVNNLEEI)) in a microsphere protected mice from Ebola virus challenge

2. Conserved nucleocapsid proteins in SARS-CoV2 could be targeted by a cytotoxic CD8 lymphocyte (CTL)-based vaccine


This study probes the in vivo efficacy of a CTL-based vaccine incorporating the previously identified and conserved Ebola virus nucleocapsid protein sequence NP43-53 in a mouse model. NP43-53 however had no effect on induction of IFNg by splenocytes in vitro. Since this may be due to inefficient MHC binding and presentation, three shorter 9-mer sub-sequences were tested, with NP44-52 triggering the biggest IFNg response. A single vaccine containing 11µM microspheres with NP44-52, CpG adjuvant and a class II epitope from Ebola virus Zaire predicted to be important for efficient vaccination was administered I.P and protected mice from Ebola challenge. The authors hypothesise that a similar approach could be used for SARS-CoV2 and identify candidate 9-mers using in silico approaches.

Impact for SARS-CoV2/COVID19 research efforts

· Utilise methods and knowledge from developing an Ebola vaccine to develop a CTL-based vaccine for SARS-CoV2/COVID19 targeting conserved nucleocapsid protein sequences

Study Type

· Ex vivo splenocyte stimulation

· Pre-clinical in vivo vaccine study (C57BL/6 mice)

· In silico study probing predicted HLA binding affinities for SARS-CoV2 sequences

Strengths and limitations of the paper

Novelty: Ebola nucleocapsid peptide sequences previously identified and tested in vitro are shown here to form a protective vaccine in vivo. Similarly, conserved nucleocapsid sequences in SARS-CoV2 and predicted HLA-binding affinities are discussed.

Standing in the field: Authors have some previous publications in this area of research. Other vaccine approaches (e.g. targeting the spike proteins) are ongoing

Appropriate statistics: Statistical methodology unclear

Viral model used: Mice were challenged with Ebola virus M. musculus/COD/1976/Mayinga-CDC-808012. All SARS-CoV2 work in silico


Translatability: Suggested next step is to collect PBMCs from COVID-19 controllers and progressors to assess the presence of a differential response to candidate peptide sequences (e.g. IFNg induction by ELISPOT)


Main limitations:

· Early data showing superiority of NP44-52 (Fig 1A) not convincing

· Not consistent with conditions that are shown (e.g. comparing different peptide sequences) and route of vaccine administration

· Little discussion of the class II epitope from Ebola virus Zaire that was incorporated in the vaccine and the effects of this alone was not shown

· Difficult to follow in pre-print form e.g. acronyms not expanded, new data referred to only in discussion, no distinction between main and supplementary figures

· Extrapolation from mouse to man not clear